Evidence map›Paper›PMID 36247016›Full record

ArticleFrontiers in cell and developmental biology2022

Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway.

Huijun Guo, Wenjing Zhang, Jiaxing Wang, Guannan Zhao, Yaohong Wang, Bing-Mei Zhu, Peixin Dong, Hidemichi Watari, Baojin Wang, Wei Li and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Huijun GuoDepartment of Pathogen Biology and Immunology, College of Life Science, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Wenjing ZhangDepartment of Genetics, Genomics and Informatics, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, United States.
Jiaxing WangDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, United States.
Guannan ZhaoDepartment of Pathology and Laboratory Medicine, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, United States.
Yaohong WangDepartment of Pathology, Immunology and Microbiology, Vanderbilt University, Nashville, TN, United States.
Bing-Mei ZhuRegenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
Peixin DongDepartment of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Hidemichi WatariDepartment of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Baojin WangDepartment of Gynecology and Obstetrics, Third Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Wei LiDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, United States.
Gabor TigyiDepartment of Physiology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, United States.
Junming YueDepartment of Pathology and Laboratory Medicine, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, United States.
University of Tennessee Health Science Center · USHokkaido University · JPJiangxi University of Traditional Chinese Medicine · CNThird Affiliated Hospital of Zhengzhou University · CNVanderbilt University · USWest China Hospital of Sichuan University · CN

Funding

Role of MTF1 in ovarian cancerR21CA216585 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI YUE, JUNMING · 2018 to 2019
$385k
NCI NIH HHS R21 CA216585
6 · The paper itself

Abstract

Cryptotanshinone (CT), a natural compound derived from

Indexed as

c-MyccryptotanshinoneFAKmetastasisovarian cancerubiquitination

Identifiers

PMID36247016
PMCPMC9554091
OpenAlexW4297540329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.